Despite the effective roll-out of COVID-19 vaccines, immunocompromised patients have a higher risk of morbidity and mortality following SARS-CoV-2 infection.
Allogeneic adoptive T-cell immunotherapy is now established as an effective approach to treat viral diseases in immunocompromised patients.
The objective of this study was to assess the safety of allogeneic virus-specific T-cell therapy in patients with COVID-19.
